Results 21 to 30 of about 423,899 (348)
BMC Pulmonary Medicine, 2017 Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum +9 more
doaj +1 more source
Pulmonary Circulation, 2021 Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Liza Botros +11 more
doaj +1 more source
Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports [PDF]
, 2015 . Pulmonary arterial dilatation associated with pulmonary hypertension may result in significant compression of local structures. Left main coronary artery and left recurrent laryngeal nerve compression have been described.
Ariff, B +6 more
core +1 more source
Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
Pulmonary Circulation, 2020 Pulmonary arterial compliance is a measure of the pulsatile afterload of the right ventricle. Lower pulmonary arterial compliance is associated with reduced right ventricular function and worse prognosis in pulmonary hypertension. The effect of pulmonary
Thenappan Thenappan +9 more
doaj +1 more source
Pulmonary Circulation, 2020 Platelet-derived growth factor is one of the major growth factors found in human and mammalian serum and tissues. Abnormal activation of platelet-derived growth factor signaling pathway through platelet-derived growth factor receptors may contribute to ...
Kang Wu +21 more
doaj +1 more source
Metformin reverses development of pulmonary hypertension via aromatase inhibition [PDF]
, 2016 Females are more susceptible to pulmonary arterial hypertension than males, although the reasons remain unclear. The hypoglycemic drug, metformin, is reported to have multiple actions, including the inhibition of aromatase and stimulation of AMP ...
Dean, Afshan +4 more
core +2 more sources
Pulmonary artery denervation for pulmonary arterial hypertension
Trends in Cardiovascular Medicine, 2021 Pulmonary arterial hypertension remains a progressive, life-limiting disease despite optimal medical therapy. Pulmonary artery denervation has arisen as a novel intervention in the treatment of pulmonary arterial hypertension, and other forms of pulmonary hypertension, with the aim of reducing the sympathetic activity of the pulmonary circulation.
Constantine, A, Dimopoulos, K
openaire +5 more sources
Risk stratification and medical therapy of pulmonary arterial hypertension
European Respiratory Journal, 2019 Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways.
N. Galiè +10 more
semanticscholar +1 more source
Schistosomiasis Pulmonary Arterial Hypertension [PDF]
Frontiers in Immunology, 2020 Pulmonary arterial hypertension (PAH) is a disease of the lung blood vessels that results in right heart failure. PAH is thought to occur in about 5% to 10% of patients with hepatosplenic schistosomiasis, particularly due to S. mansoni. The lung blood vessel injury may result from a combination of embolization of eggs through portocaval shunts into the
Virginia Pacheco Guimaraes +24 more
openaire +6 more sources
Genetics of Pulmonary Arterial Hypertension [PDF]
Seminars in Respiratory and Critical Care Medicine, 2009 Tremendous progress has been made in understanding the genetics of pulmonary arterial hypertension (PAH) since its description in the 1950s as a primary disorder of the pulmonary vasculature. Heterozygous germline mutations in the gene coding bone morphogenetic receptor type 2 (BMPR2) are detectable in the majority of cases of heritable PAH, and in ...
Joshua D. Chew +2 more
openaire +4 more sources